










































Cachexia is a hypermetabolic wasting syndrome 
involving the progressive depletion of adipose tissue 
and skeletal muscle mass, irrespective of nutritional 
intake. It has the highest incidence in patients with 
gastrointestinal and pancreatic cancers (83-87%) [1]. At 
least 20% of cancer deaths are directly caused by 
cachexia [1]. Cachexia is associated with severe weight 
loss, muscle wasting, weakness and fatigue and causes 
psychosocial distress and dependency upon others; 
significantly impairing quality of life [2]. Importantly, 
reversal of weight loss has been shown to be associated  
 
 








































with increased longevity in tumor-bearing (TB) mice 
[3]. Therefore, a better understanding of the molecular 
process underlying skeletal muscle wasting due to 
cancer cachexia is critical in designing intervention 
strategies; beneficing both the quality and longevity of 
cachectic patients. 
 
Inappropriate chronic stimulation of downstream 
signaling molecules by constant influx of tumor and 
host-derived cytokines affects normal homeostasis and 
energy metabolism, resulting in altered muscle 
respiration, muscle fatigue and degradation. Raised 
levels of Interleukin (IL)-1β, IL-6, Tumor Necrosis 
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factors in cachexia [1]. TNF-α and Interferon-gamma 
(IFN-γ) have been shown to be capable of 
downregulating muscle-specific gene products and 
activating Nuclear Factor-kappa B (NF-κB) resulting in 
impaired myogenesis [4]. Additionally, there is 
substantial evidence implicating a role of IL-6 in the 
pathogenesis of cancer cachexia [5]. Development of 
cachexia in pre-clinical mouse models and clinical data 
correlate with increased circulating IL-6 [6-11]. 
Blockade of IL-6 action has significantly reversed 
skeletal muscle wasting in rodent models [11-14]. 
Moreover, IL-6 alone has been shown to cause skeletal 
myofiber changes; both structural and metabolic [15, 
16]. Therefore, a complex network of cytokine 
signaling is involved in the pathogenesis of cancer 
cachexia and cytokines such as IL-6, may play a 
dominant role. 
 
IL-6 is a pleiotropic cytokine which has both pro- and 
anti-inflammatory properties [17]. IL-6 mediates its 
action via IL-6 receptor (IL-6RA) which hetero-
dimerizes with the gp130 partner [18]. The JAK-STAT 
signaling pathway is then activated and promotes the 
transcription of Suppressor of Cytokine Signaling 
(SOCS) 3 as a negative feedback mechanism [18]. 
SOCS3 has been shown to interact with molecules in 
metabolic pathways and modulate their signaling [19]. 
Therefore, this raises the question of whether signaling 
involving SOCS3 may crosstalk with myogenic 
pathways under chronic IL-6 stimulation during cancer 
cachexia. 
 
Myocyte Enhancer Factor (MEF) 2C is a myogenic 
transcription factor that plays a critical role in skeletal 
muscle development and differentiation. It regulates 
genes encoding proteins involved in maintaining 
sarcomeric integrity and function, such as M-line and Z-
line proteins [20]. The role of MEF2C in postnatal 
muscle maintenance has been highlighted in a skeletal 
muscle specific Mef2c knockout mouse model, whereby 
sarcomeres appeared to be disorganized and fragmented 
[20]. MEF2 also regulates genes with diverse functions 
in skeletal muscle such as oxygen transport e.g. 
myoglobin [21, 22]. Suppression of MEF2C has been 
reported in several skeletal muscle disorders e.g. 
muscular dystrophy and microgravity induced atrophy 
[23, 24]. Moreover, Mef2c  has been shown to be 
downregulated in different wasting conditions including 
cancer cachexia [25]. 
 
In this study, the Colon 26 (C26) carcinoma mouse 
model of cachexia was used for the molecular and 
ultrastructural analyses in wasted skeletal muscle [3, 5, 
26]. IL-6 is predominantly responsible for skeletal 
muscle changes and aberrant metabolism in this model 
[6, 27]. In this study we demonstrate a novel association 
between dysregulated MEF2C gene expression and 
prominent ultrastructural changes in muscle structural 




Features of the C26 carcinoma model  
 
Reduced body and muscle weight associated with 
elevated plasma IL-6 levels was observed in C26-
bearing mice at the experimental endpoint for weight 
loss in this study (Table 1). The weight loss was 
associated with myofiber atrophy with a more 
prominent change in type 2 myofiber cross-sectional 
area and agreed with previous study which showed the 
change in diameter ([30]; Figure 1).  
 
Increased expression of IL-6 signaling molecules 
 
Expression of the Socs3  gene, a direct target of 
activated STAT3 downstream of the IL-6 receptor, has 
been shown to correlate negatively with skeletal muscle 
protein content after IL-6 infusion [15]. A significant 
elevation of Socs3  transcription was specific to C26-
bearing mice at the endpoint (5.64-fold; p<0.001; 
Figure 2A). Similarly, gene expression of the IL-6 
receptor subunit Il-6ra was upregulated in C26-bearing 
mice (18.0-fold; p<0.001). A 1.58-fold increase was 
also seen for its partner, gp130 in C26-bearing mice 
compared to the non-TB controls (p<0.01). Receptors 
for TNF-α also demonstrated a significant increase in 
C26-bearing animals (Tnfr1: 1.39-fold, Tnfr2: 1.62-fold; 
p<0.01). Longitudinal studies demonstrated that the 
increase in circulating IL-6 preceded a significant 
elevation of the gene expression of Socs3  and  Il-6ra 
(Figure 2B). 
 
Ultrastructural changes in sarcomeric integrity in 
muscle 
 
Analysis of muscle from control mice using electron 
microscopy showed the parallel register of myofibrils 
consisting of sarcomeres in series (Figure 3A). The 
sarcomere is the functional and structural unit for 
contraction and is demarcated by two Z-lines. Sections 
from cachectic muscle harvested at the endpoint 
exhibited altered ultrastructure to varying degrees in 
different myocytes (Figure 3B-C). Vesicle-like 
structures were apparent at the Z-lines, and invaded into 
surrounding myofibrils (Figure 3C (i); arrow) [31]. 
Sarcomere disintegration was also evident. Extreme 
changes were seen where the sarcomeres appeared 
‘torn’ at the M-line (Figure 3C (ii); asterisk). In other 
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interstitial spaces between myofibrils (Figure 3C (iii)). 
 
Ultrastructural changes in mitochondria in muscle 
  
The normal appearance of mitochondria with densely 
packed cristae and homogenous matrix was diminished 
in muscles of C26-bearing mice (Figure 3D). 
Mitochondrial changes such as the presence of electron-
lucent areas (Figure 3D (ii); arrow) and swelling (Figure 
3D (iii); triangle) were seen. Some mitochondria were 
associated with multiple vesicle-like structures which 











































3D (iv); asterisk). A reduced proportion of normal 
mitochondria in C26-bearing mice (57.5%) compared to 
non-TB mice (96.1%; p<0.01; Figure 3E) was apparent. 
In contrast, the proportion of mitochondria with locally 
electron-lucent matrix increased in the C26 cachectic 
group (26.7%) compared to the control group (2.76%; 
p<0.05). Swelling and/or fragmentation features of 
cristae were more apparent in mitochondria of C26-
bearing mice (13.2%) compared to the controls (0.95%; 
p<0.01). More mitochondria were associated with 
vesicles in the C26 mice (2.60%) compared to controls 























































































Altered expression of MEF2C and target genes in 
structural maintenance and energy homeostasis 
 
Mef2c  mRNA was significantly suppressed in C26-
bearing mice compared to non-TB controls (3.13-fold 
reduction; p<0.001; Figure 4A). The change was also 
reflected at the protein level with a 1.32-fold reduction 
(p=0.05; Figure 4B). Sarcomeric subtype-specific gene 
expression changes  were observed for the gene 
encoding a Z-line protein, Myozenin (Myoz). Myoz1 was 
suppressed significantly in cachectic muscle (1.94-fold 
reduction; Figure 4C) while Myoz2 i n  c o n t r a s t  w a s  
significantly elevated in C26-bearing mice (1.36-fold). 
Changes in Myoz3 expression were similar to Myoz1 but 
the extent of downregulation was greater in the 
cachectic group (10.1-fold reduction). Myokinase (Mk) 
was significantly downregulated in C26-bearing 
mice16-fold reduction; Figure 4D). Myoglobin ( Mb) 
was also significantly suppressed in C26-bearing mice 




































Altered expression of calcineurin 
 
One of the important upstream regulators of MEF2C is 
calcineurin, which is a calcium/camodulin-activated 
protein phosphatase [32]. A 3.21-fold reduction of the 
calcineurin catalytic subunit PP2B-Aα was observed in 
C26-bearing mice compared to the non-TB controls 




The data presented in this study provide further insights 
into the molecular basis of muscle wasting due to cancer 
cachexia and highlight the potential role of MEF2C in the 
development of cachexia. A novel observation of 
dysregulated myogenic gene expression and associated 
ultrastructural mitochondrial and sarcomeric changes in 
the C26 mouse model of can cachexia suggests 
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Figure  3.  Ultrastructural  changes  in  GAS.
(A)  Representative  electron  micrograph  of
muscle from non‐tumor‐bearing (non‐TB) control
mice. Magnification: x 8000. (B) Representative
electron  micrographs  of  muscle  from  C26‐
bearing  mice.  Magnification:  x  8000  (i  &  ii),
x10000 (iii). (C) A higher magnification of muscle








mitochondria  with  different  morphologies  in
C26‐bearing  and  non‐TB  mice.  Data  are
presented as arithmetic means ± SEM. *p<0.05,
**p<0.01 (n=3). A reduced proportion of normal
mitochondria  and  increased  percentage  of
abnormal  mitochondria  with  various  changes
were  seen  in  C26‐bearing  mice  compared  to
non‐TB animals. 
   











































Significant changes in gene expression of relevant 
molecules in the context of increased circulating IL-6 
were seen in muscle from C26-bearing mice. Altered 
Socs3 mRNA levels have previously indicated 
perturbations in IL-6 signaling [15]. In this study, 
elevated Socs3 and Il-6ra likely resulted from the action 
of circulating IL-6 on skeletal muscle during cancer 
cachexia, as the rise in gene expression appeared to 
follow elevation of circulating IL-6 (Figure 2B). The 
extent of Il-6ra elevation in cachectic muscles 
compared to controls was greater than that of Socs3; 












































sion in cachectic muscles could further propagate IL-6 
signaling. Moreover, the IL-6/IL-6RA complex has 
been shown to be internalized and degraded, therefore 
production of IL-6 receptor would be essential to 
sustain IL-6 signaling [33]. A soluble form of IL-6RA 
may be generated by proteolytic cleavage or alternative 
splicing [34]. Therefore, upregulated gene expression of 
Il-6ra in muscle may increase production of soluble IL-
6RA and its subsequent release into the circulation, 
impacting on tissues other than the muscle. This may 
explain the unexpected fold-changes in the receptor 
compared to the downstream target, Socs3. Gp130, 
Figure  4.  Expression  of  MEF2C  and  gene  targets  governing  muscle  structural  integrity  and  energy
homeostasis. Expression of MEF2C at (A) gene (n=4) and (B) protein levels (n=3). Expression of MEF2C
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ubiquitously expressed and non-specific for IL-6; hence 
may explain for the lesser degree of elevation. Receptors 
for TNF-α, also showed a much lower elevation, 
indicating that TNF-α signaling may not be as crucial as 



























We have identified novel ultrastructural features in 
gastrocnemius muscles of C26-bearing mice with 
myocytes demonstrated to have varying degrees of 
ultrastructural changes. The data suggests that 
disruption of myofibrils may have begun at the 
sarcomeric Z-lines (Figure 3A-C). In areas with a 
complete loss of sarcomeres, a reduced contractility 
would be assumed as the functional unit, i.e. sarcomeres 
were ‘torn’ or had undergone breakdown. The observed 
ultrastructural changes in the skeletal muscle of C26-
bearing mice are novel and may partly explain the 
asthenia and fatigue which patients with cancer 
cachexia experience. We propose that the observed 
ultrastructural changes are linked with altered gene 
expression of Mef2c  and its target genes. The 
importance of MEF2C in regulating postnatal 
sarcomeric integrity and muscle function has been 
previously suggested [20]. Gene expression of Myoz1 
and  Myoz3 were downregulated along with Mef2c 
(Figure 4). Expression of Myoz has been shown to be 
suppressed with Mef2c muscle-specific deletion, hence 
likely to be transcriptionally regulated by MEF2C [20]. 
Myozenins have been reported to interact with a number 
of Z-line-localised proteins including α-actinin and 
telethonin in addition to modulating signal transduction 
via calcineurin [35-37]. Therefore, their reduced 
expression may compromise muscle integrity, 
especially at the Z-line. However, the disconnection 
between  Mef2c  and  Myoz2 gene expression suggests 
negative regulation by MEF2C in the presence or 
absence of possibly another regulatory molecule or an 
alternative, as yet unknown regulatory mechanism 
independent of MEF2C. For instance NF-κB has 
previously been shown to be a mediator of Myoz2 
transcription but not Myoz1 in C2C12 myogenic cells 
[38]. NF-κB has been associated with skeletal muscle 
wasting which regulates protein degradation and the 
ubiquitin-proteasome pathway [39]. Therefore, it is not 
unreasonable to speculate that different isoforms of the 
Myoz family could be affected via different pathways 







































subunit  of  calcineurin  was  reduced  at  the  protein  level  at
endpoint cachexia. Data are presented as arithmetic means ±
SEM.  **p<0.01  compared  to  non‐tumor‐bearing  (non‐TB)
controls (n=3).  
Figure 6. A proposed model of IL‐6 dependent loss of





periphery  of  a  myofiber.  This  might  affect  its  function  and
hence impact on the downstream targets like MEF2C. Since
MEF2C  is  a  key  regulator  of  many  myogenic  and  energy
homeostatic molecules, any perturbation in its activity could
greatly  affect  muscle  performance  and  integrity.  Such
alterations  may  accelerate  muscle  breakdown  and
disintegration  of  the  tissue  contributing  to  fatigue  and
weakness during cancer cachexia. 
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mitochondria of cachectic muscle (Figure 3D). Semi-
quantification of mitochondrial morphological changes 
provided comprehensive information on the disruption 
of energy homeostasis in skeletal muscle. These 
changes included electron–lucent areas which 
corresponded to a loss of cristae in these mitochondria; 
suggesting defective oxidative phosphorylation to 
generate ATP. In addition, swollen mitochondria, which 
are reported to be associated with cellular ATP 
depletion, were present [29]. Vesicle-like structures, 
likely to be autophagic bodies were also observed in 
some mitochondria which suggested eventual 
mitochondrial loss via autophagy in cachectic muscle 
[31]. These observations may reflect the reduced gene 
expression of Mk and Mb, which serve to replenish ATP 
from ADP in the cytosol and transport oxygen 
respectively. Importantly, myokinase-deficient skeletal 
muscle has been associated with reduced energy 
efficiency with contractile performance maintained via 
compensatory mechanisms e.g. via creatine kinase [40]. 
This however does not appear to be operational in 
muscle loss due to cancer cachexia (unpublished data). 
Moreover,  Mb has been known as a MEF2 
transcriptional target; further establishing the role of 
MEF2C during cancer cachexia in compromising not 
only structural integrity but also energy metabolism 
[41]. 
 
The reduced expression of the catalytic subunit of 
calcineurin suggested a pathway for the reduced Mef2c 
expression seen (Figure 5). Interestingly, calcineurin 
has been shown to be delocalized by SOCS3 in skeletal 
muscle from the usual site along the Z-line in a SOCS3 
transgenic mouse model [42]. Therefore, we propose a 
novel link between elevated plasma IL-6 and 
suppressed Mef2c transcription via calcineurin (Figure 
6). This raises a new perspective for muscle wasting in 
cancer cachexia whereby degradation could be 
accelerated through disruption of sarcomeric integrity. 
Elucidating the mechanism of such disruption would 
provide new molecular targets for interventions in 
controlling muscle loss. Moreover, it would also be 
beneficial in the context of aging since mitochondrial 
dysfunction, reduced insulin sensitivity and declined 
muscle performance are often presented in aged people 
[43]. It should also be noted that MEF2C is a 
transcriptional regulator of Glucose transporter type 
(GLUT) 4, the main glucose transporter in skeletal 
muscle, hence the disrupted MEF2C signaling could 
impact on insulin sensitivity and should be addressed in 
future studies [44]. Therefore it appeared that MEF2C is 
a promising target for intervention strategies to reverse 
or stabilize muscle loss in cachexia. Future research into 
molecular mechanisms for muscle loss and intervention 
strategies to correct the effects of dysregulated MEF2C 
would greatly enhance our understanding of cancer 
cachexia progression and ultimately benefit cancer 
patient quality of life by improving muscle strength. 
 
MATERIALS AND METHODS 
 
C26 mouse model of cachexia.  C26 carcinoma cells 
(Amgen, Thousand  Oaks, California) were  maintained 
in RPMI/Penicillin Streptomycin (PS) in a humidified 
atmosphere with 5% CO2 at 37°C. Male Balb/c-DBA 
hybrid mice (10-11 weeks old) were obtained from the 
Animal Resources Centre (Perth, WA, Australia) and 
housed at the Molecular Physiology Unit (ANZAC 
Research Institute, Concord, NSW, Australia). Mice 
were maintained at a constant temperature (22°C) on a 
12 hr light: 12 hr dark cycle. Standard rodent chow and 
water  ad libitum were freely accessible. All animal 
work prior to culling was conducted under approval 
(Sydney South West Area Health Service Animal 
Welfare Committee; protocol number 2007/006). For 
tumor inoculation, 1 x 10
6 C26 cells in 100 μl RPMI/PS 
were subcutaneously inoculated in the upper right flank 
of the mice. Non-tumor-bearing (Non-TB) control mice 
were injected with 100 μl RPMI/PS. 
 
Plasma IL-6 measurements. Mice were anesthetised at 
the endpoint (Day 8, 10, 12 or 14) by intraperitonial 
injection of ketamine (100 mg/kg) and xylazine (50 
mg/kg). Blood was then collected by cardiac puncture 
and spun at 5000 x g for 5mins for plasma isolation. 
Quantikine® Mouse IL-6 Immunoassay kit (R&D 
Systems, Minneapolis, MN, USA) was used to 
determine plasma IL-6 concentration following the 
manufacturer’s protocol. 
 
Tissue weights and tissue collection.  Mice were 
sacrificed by cervical dislocation at 2 pm. For the 
longitudinal study, mice were culled on day 8, 10, 12 or 
14 post-tumor inoculation. For single time-point 
experiments, endpoint was selected so that percentage 
weight loss in C26-bearing mice ranged from 13-18%, 
which was within the ethnical limit of 20%. Mice were 
culled on day 14 and 16 post-tumor inoculation to 
account for the inter-individual variability of weight 
loss. In preparation for histological studies, lower 
hindlimbs were embedded in Tissue-Tek® (Pro-Sci 
Tech,Thuringowa, QLD, Australia) and frozen over 
isopentane cooled on liquid nitrogen. Individual 
muscles were isolated, weighed and subsequently snap-
frozen in liquid nitrogen and stored at -80°C.  
 
Immunohistological studies. Frozen lower hindlimbs 
were sectioned at 7-10μm on a Leica CM1900 cryostat. 
Immunohistochemistry for myosin heavy chain (MHC) 
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performed as previously described [28]. Each section 
was digitally photographed with 1.25 x and 10 x 
objectives for cross-section of the whole lower hindlimb 
and the soleus respectively (Zeiss Axio Imager 
A1microscope with a Spot Insight Firewire camera 
Model 11.3 and Spot Version 4.0.2 software; Diagnostic 
Instrument Inc., Sterling Heights, MI, USA). Myofiber 
counts and measurements were then performed on the 
soleus muscle. 
 
Electron microscopy. Ultrathin sections (70 nm) were cut 
from fixed gastrocnemius muscles and stained with 2% 
uranyl acetate (aqueous) and 2% lead citrate and 
examined under a Jeol1400 transmission electron 
microscope (Electron Microscopic Unit, UNSW, NSW, 
Australia) at a voltage of 100 kV. Semi-quantitative 
scoring was performed according to [29] with 
modifications. Electron micrographs taken at a 
magnification of x 25000 were used. Multiple images 
were randomly taken from one grid. Mitochondria were 
categorized into four groups according to their 
morphology: unchanged (group 1), electron-lucent matrix 
(group 2), swelling/ fragmentation of cristae (group 3), 
association with vesicle-like structures (group 4).  
 
Gene expression studies. Total RNA was extracted from 
gastrocneumius muscle using TRIzol® reagent 
(Invitrogen, Carlsbad, CA, USA). RNA (0.5 μg) was 
used in a first-strand reaction with oligo dT primers 
(Invitrogen) and Superscript® reverse transcriptase 
(Invitrogen). Real-time quantitative polymerase chain 
reaction (PCR) was performed using specific primers 
(Sigma, Castle Hill, NSW, Australia; Supplementary 
Table 1) on a Corbett RG 6000 rotor machine (Corbett 
Research, Mortlake, VIC, Australia). Each standard 
reaction contained 5 μl sample cDNA (1:100 dilution); 
12  μl SYBR® Green (Invitrogen); 6 μl RNase free 
water and 1 μl each of forward and reverse primers 
(300nM).  TATA box-binding protein ( Tbp) and 
ribosomal protein, large, P0 (36B4) were used as the 
housekeeping genes to obtain normalization factors 
from geNorm Version 3.5 (Ghent University Hospital, 
Center for Medical Genetics, Ghent, Belgium). 
Normalization for candidate gene expression was 
corrected against housekeeping gene expression; each 
candidate gene was divided by its normalization factor 
for each mouse muscle sample. 
 
Protein expression studies.  Muscle extracts were 
prepared by homogenising gastrocnemius muscle in ice-
cold RIPA buffer (Cell Signaling Technology, Danvers, 
MA, USA) supplemented with protease inhibitor 
(Roche Diagnostics, Sydney, Australia), incubated on 
ice for 1 hr. Supernatant lysates were collected 
following centrifugation at 14000 x g for 10 min at 4°C. 
Twenty micrograms of extract were subjected to 10% 
SDS-polyacrylamide gel electrophoresis and transferred 
to PVDF membranes (Bio-Rad Laboratories, 
Gladesville, NSW, Australia). Blocking was performed 
in 1% polyvinylpyrrolidine-40 (PVP-40) – 1 x TBST 
(20 mM Trizma Base [pH7.5], 135 mM NaCl, 0.1% 
Tween 20) followed by 3% skim milk powder-1% PVP-
40 – 1 x TBST. Primary and secondary antibodies were 
diluted in 0.5% PVP-40 – 1 x TBST and 1% PVP-40 – 
1 x TBST for an overnight and 1 hr incubation at 4°C 
and room temperature respectively. Washes were 
performed in 1 x TBST for 5 to 10 min and repeated 
five times. Specific proteins were visualized by 
SuperSignal West Femto Substrate (Thermo Scientific 
Inc., Scoresby, VIC, Australia). Antibodies to MEF2C 
and PP2B-A were obtained from Santa Cruz 
Biotechnology (California, USA). 
 
Statistical analysis.  Data are presented as arithmetic 
means ± SEM. Two-tailed unpaired t-tests were 
performed to compare C26-bearing and non-TB control 
groups. A P value of <0.05 was considered as 
significant. GraphPad Prism 5.03 (GraphPad Software, 
San Diego, CA) was used for all data analysis and 
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  Forward 5’Æ 3’  Reverse 5’Æ3’ 
Socs3  GGCCACCCTCCAGCATCTTTGTCG GTGGCAGCTCCCCCTCCCCTCAG 
Il6ra  CTCCCGGTGGCCCAGTACCA TGCACTGGGGCGAGGACACT 
Gp130  CATCCCCAGCCCCCACGTCA TCCTCTGGCAGGAGCGGCTT 
Tnfr1  AGCCCCTGCTTCAACGGCAC AACCAGGGGCAACAGCACCG 
Tnfr2  CAGTGCCCGCCCAGGTTGTC CGCACACACGGTGTCCGAGG 
Mef2c  GCTGTTCCAGTACGCCAGCAC AGTGCGTGGGGTGAGTGCATAA 
Myoz1  CGGGGAGAGCCGACCACCAA CTGAGCTCTCCCGGCCACCT 
Myoz2  GCCCCTCAACTCCGCCCAAC TCCGGATCGCTGCCAATCGC 
Myoz3  TGCAGGCCATCCTGGCGAGT CGTGCGTCTCGGAGTGGTGG 
Mk CCTGCTTCGGGCAGAAGTCAG  GTAGCCGTCGATCAGGAAGCC 
Mb AGTGATGGGGAGTGGCAGCTG  ACCATGCTTCTTCAGGTCCTCTGA 
Tbp ATTCACCCCCACTGAGACTGA CTCGATCCCAGTAGACGGTC 
36B4 CGACCTGGAAGTCCAACTAC ATCTGCTGCATCTGCTTG 
 